Advertisement
Advertisement
U.S. markets open in 5 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
1.2400-0.0100 (-0.80%)
At close: 04:00PM EST
1.2300 -0.01 (-0.81%)
After hours: 06:49PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close1.2500
Open1.2800
Bid0.0000 x 1300
Ask0.0000 x 2200
Day's Range1.2200 - 1.3300
52 Week Range1.2200 - 9.7800
Volume544,625
Avg. Volume1,229,560
Market Cap71.578M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-1.2760
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for UBX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Unity Biotechnology, Inc.
    CYTK: Lowering target price to $35.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022

    12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with aflibercept Additional pipeline programs targeting age-related diseases continue to advance SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology

  • GlobeNewswire

    UNITY Biotechnology Reports Granting of New Employment Inducement Award

    SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted a new employee a stock-based award covering an aggregate of 4,500 shares of UNITY common stock, including options to purchase an aggregate of 4,500

  • GlobeNewswire

    UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

    SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized t

Advertisement
Advertisement